How should a child with rhabdomyosarcoma who has completed his final chemotherapy and same‑day radiotherapy, with no residual tumor, be acutely managed and evaluated after experiencing a seizure?

Acute Management of Post-Treatment Seizure in Pediatric Rhabdomyosarcoma

This child requires immediate seizure management following established pediatric protocols, urgent neuroimaging with contrast-enhanced MRI to exclude treatment-related complications, and initiation of anticonvulsant therapy with levetiracetam as first-line agent.

Immediate Acute Management

Seizure Control Protocol

• Assess circulation, airway, and breathing (CAB) and provide airway protection interventions, administer high-flow oxygen, and check blood glucose level immediately 1
• For convulsive seizures: Administer lorazepam 0.1 mg/kg (maximum 2 mg) intravenously; repeat dose after at least 1 minute (maximum of 2 doses) to control seizures 1
• Add levetiracetam 40 mg/kg (maximum 2,500 mg) IV bolus in addition to any maintenance dose 1
• If seizures persist: Add phenobarbital IV at loading dose of 10-20 mg/kg (maximum 1,000 mg) and transfer to pediatric intensive care unit (PICU) 1
• Consider corticosteroids if cerebral edema is suspected 1

Maintenance Anticonvulsant Dosing After Seizure Resolution

• Lorazepam 0.05 mg/kg (maximum 1 mg) IV every 8 hours for 3 doses 1
• Levetiracetam 30 mg/kg IV every 12 hours or increase prophylaxis dose by 10 mg/kg (to 20 mg/kg) IV every 12 hours (maximum 1,500 mg) 1
• Phenobarbital 1-3 mg/kg IV every 12 hours if required 1

Urgent Diagnostic Evaluation

Neuroimaging Requirements

Contrast-enhanced cerebral MRI is mandatory to rule out multiple potential etiologies in this clinical context 1:

• Treatment-associated neurotoxicity from chemotherapy or radiotherapy 1
• Cerebral edema (best visualized on T2-weighted or FLAIR sequences) 1
• Intracranial hemorrhage or ischemia related to treatment 1
• Infectious complications (particularly given immunosuppression from chemotherapy) 1
• Metabolic disturbances 1
• Rare CNS involvement by rhabdomyosarcoma (though stated no residual cancer) 1

Additional Diagnostic Studies

• Electroencephalography (EEG) to rule out nonconvulsive status epilepticus, estimate future seizure risk, and differentiate from other causes of altered mental status 1
• Continuous EEG monitoring if seizures are refractory to initial treatment 1
• Laboratory evaluation: Complete blood count, comprehensive metabolic panel, magnesium, calcium, phosphate levels to identify metabolic derangements 1
• Blood and CSF examination if infectious etiology suspected 1

Anticonvulsant Selection and Management

First-Line Agent

Levetiracetam is the preferred anticonvulsant for this patient 1:

• Superior efficacy and overall good tolerability profile 1
• No drug interactions with chemotherapy agents (critical consideration given recent chemotherapy completion) 1
• Does not induce hepatic metabolism unlike phenytoin, carbamazepine, or phenobarbital 1
• Psychiatric side effects remain a concern but are manageable 1

Alternative Agents

• Lamotrigine has good antiseizure activity but requires several weeks to reach therapeutic levels, making it less suitable for acute management 1
• Lacosamide may be considered as add-on therapy if monotherapy fails 1
• Valproic acid should be avoided in females of childbearing potential and requires monitoring for drug interactions 1
• Avoid first-generation agents (phenytoin, carbamazepine, phenobarbital) due to significant drug interactions with steroids and chemotherapy agents 1

Critical Differential Considerations

Treatment-Related Complications

Given same-day completion of chemotherapy and radiotherapy, consider:

• Radiation-induced cerebral edema: May require dexamethasone 4-16 mg/day as single daily administration, tapered to lowest effective dose 1
• Chemotherapy neurotoxicity: Particularly relevant with recent treatment completion 1
• Posterior reversible encephalopathy syndrome (PRES): Can occur with chemotherapy agents 1

Infection Risk

• Immunosuppression from chemotherapy increases risk of CNS infections 1
• Consider Pneumocystis jirovecii pneumonia (PJP) prophylaxis with trimethoprim-sulfamethoxazole if steroid treatment exceeds 4 weeks or lymphocyte count <1000/ml 1

Common Pitfalls to Avoid

1. Do not initiate prophylactic anticonvulsants without documented seizure - evidence shows no benefit in reducing first seizure risk 1
2. Avoid enzyme-inducing anticonvulsants that interfere with chemotherapy metabolism 1
3. Do not delay neuroimaging - new seizures in cancer patients mandate urgent MRI to exclude progression or complications 1
4. Avoid prolonged steroid therapy without clear indication due to toxicity profile including immunosuppression, metabolic derangements, and impaired wound healing 1
5. Do not assume seizure is benign - in post-treatment rhabdomyosarcoma patients, seizures often indicate treatment-related complications requiring specific intervention 1

Ongoing Management Strategy

Secondary Seizure Prophylaxis

The vast majority of patients experiencing a seizure should be placed on anticonvulsant secondary prophylaxis, at least transiently 1:

• Continue levetiracetam at maintenance dosing 1
• Monitor serum levels to assess compliance and evaluate for drug-related side effects 1
• Tapering consideration: If MRI shows no structural abnormality and treatment-related complications resolve, consider tapering anticonvulsants after appropriate observation period 1

Follow-Up Monitoring

• Question patient and caregivers about seizure occurrences at each follow-up visit 1
• Repeat neuroimaging if seizure control worsens, as this may herald disease progression or treatment complications 1
• Educate patients and caregivers on seizure management and emergency contact procedures 1